Summary of mean (SD) change from baseline at Week 24 in PsA-modified SvdH (observed data) by treatment group and observed ACR response at Week 24.
| Response at Week 24 | IV Placebo | IV Golimumab, 2 mg/kg |
|---|---|---|
| ACR20 | ||
| Responder, n | 60 | 181 |
| Change in total PsA-modified SvdH | 1.08 (2.92) | −0.60 (2.10) |
| pa | < 0.001 | |
| Nonresponder, n | 48 | 153 |
| Change in total PsA-modified SvdH | 2.48 (4.62) | 0.41 (2.63) |
| pa | < 0.001 | |
| ACR50 | ||
| Responder, n | 16 | 126 |
| Change in total PsA-modified SvdH | 0.59 (2.15) | −0.56 (2.20) |
| pa | 0.0413 | |
| Nonresponder, n | 198 | 103 |
| Change in total PsA-modified SvdH | 2.21 (4.35) | −0.18 (2.30) |
| pa | < 0.001 | |
| ACR70 | ||
| Responder, n | 9 | 77 |
| Change in total PsA-modified SvdH | 0.17 (1.56) | −0.95 (2.17) |
| pa | 0.1017 | |
| Nonresponder, n | 206 | 153 |
| Change in total PsA-modified SvdH | 2.17 (4.30) | −0.11 (2.24) |
| pa | < 0.001 |
↵a P value derived from an ANCOVA with van der Waerden rank test. ACR20/50/70: ≥ 20/50/70% improvement in American College of Rheumatology response criteria; IV: intravenous; PsA: psoriatic arthritis; SvdH: Sharp/van der Heijde score.